"(€ million);2023;2022;2021
Impairment of other intangible assets, net of reversals (excluding software);932;(454);192
Marketed products;—;(1,561);42
Biopharma;—;(1,526);1
Consumer Healthcare;—;(35);41
Research and development projects and technology platforms;896;1,107;150
Others;36;—;—"
